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Abstract: 
Background: Cetuximab is used for the treatment of RAS wild-type metastatic colorectal 
cancer patients. Standard administration schedule is once a week however the 
bioequivalence of an every-other-week (EOW) schedule was demonstrated. 
Methods: We compared a base case scenario of 100% weekly administration to an every-
other-week (EOW) at 50% or 100%. Medical examinations, patient management and loss 
of productivity were considered.  
Results: Base case was estimated at €100.6 million versus € 92.8 million and €84.9 
million of EOW 50% and 100% which showed a cost reduction of 8% and 16% 
respectively. Indirect costs accounted for 65% in both scenarios. 
Conclusions: The adoption of an EOW administration schedule of Cetuximab reduced 
direct and indirect costs substantially.  
Introduction
Colorectal cancer (CRC) is a major public health issue of industrialized countries. 
The management of the high number of patients with metastases heavily impact on oncology 
services and health resources [1-3]. Moreover, a great increase in social and economic 
burden is anticipated by changing demographics and the ageing of the population 
worldwide.  
CRC is a highly lethal cancer, depending on its focalization, after 3-5 years of 
diagnosis the death rate reaches 40-60% [4]. In Italy, according to the Italian Association of 
Cancer Registries (AIRTUM) and the Italian Association of Medical Oncology (AIOM), 
there are over 464,000 patients with a previous diagnosis of colorectal carcinoma (53% 
males), the second most common cancer affecting 14% of all cancer patients [5]. With 
regard to the incidence, 53,000 new diagnoses of colorectal cancer are estimated in 2017. 
Furthermore, CRC represents the second most frequently diagnosed cancer among men 
(13%) and women (16%), preceded by prostate and breast cancers respectively [5].  
 In the metastatic setting, current treatment options for RAS wild-type patients include 
the administration of chemotherapy  in combination with an anti- epidermal growth factor 
receptor (EGFR) antibody. Indeed, these recommendations are based  on significant 
improvements in terms of overall survival provided by the addition of anti-EGFR antibodies, 
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namely cetuximab and panitumumab, to standard chemotherapy regimens, such as Folfox 
or Folfiri  [5, 6]. In particular, cetuximab is a chimeric monoclonal immunoglobulin G1 
(IgG1) administered following a weekly treatment schedule of 400 mg per BSA as loading 
dose for the first week, and 250 mg per body surface area (BSA) in the following weeks [7]. 
Due to the long Cetuximab half-life of 66-98 hours, its administration every other week 
(EOW) is theoretically possible although the weekly schedule was validated in clinical 
studies. Pharmacodynamics (PD) and pharmacokinetic (PK) studies demonstrated the 
bioequivalence as well as the efficacy of an EOW dosing schedule [6, 8-10] in mCRC RAS 
wt patients [11], however the economic consequences have yet to be thoroughly 
investigated. The objective of the analysis was to assess the impact on National Health 
Service budget of a bi-montly administration method (EOW) of Cetuximab in patients 
diagnosed with mCRC RAS wt in Italy. 
Methods 
An excel-based model was developed to estimate the economic impact of an (every 
other week) EOW compared to weekly administration of Cetuximab among patients with 
mCRC RAS wt. We performed a review of the epidemiological and economic literature. 
The budget impact model was developed following the guidelines suggested by the 
International Society of Pharmacoeconomics and Outcome Research (ISPOR) [12, 13]. 
Epidemiological parameters 
The size of the eligible population in Italy was identified according to therapeutic indication 
of Cetuximab. As reported in Table 1, incidence rates provided by the Italian Association 
of Cancer Registries [5] were used to estimate the cohort of individuals annually diagnosed 
with CRC on the total resident population at 2017 [14]. Then, the number of patients 
diagnosed with mCRC RAS wt was estimated considering the average between those that 
presented metastasis at initial diagnosis and those that were likely to develop metastases 
after [15]. Precisely, the model assumed that about 21,730 patients had a metastatic CRC 
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and 5,067, corresponding to 23.3%, were RAS wild type [16, 17]. Of these, 2,787 patients 
(55%) were treated with first line Cetuximab [18].  
Table 1 – Epidemiological parameters to identify the population diagnosed with CRC-RASwt – Italy 
2017 
Epidemiologic Parameters mCRC Model Parameter Population Ref 
Residential population 60,589,445 [14] 
CRC incidence 0.087% 53,000 [5] 
mCRC wt population 41.0% 21,730 [15] 
Popolazione mCRC wt - EGFR+ 23.3% 5,067 [16, 17] 
Patients treated with Cetuximab 55.0% 2,787 [18] 
Time Horizon 
The second step included the definition of the time horizon. With reference to mCRC 
RAS wt patients, a 6-months time horizon has been considered.  Irrespective of primary 
tumor location [19], this figure reflects the overall duration of cetuximab as part of the first-
line treatment, either in association with chemotherapy or after withdrawal of chemotherapy 
(maintenance) [20] 
Current and future treatment mix 
In keeping with the current administration schedule, a base case scenario was set 
considering 100% of patients treated with a weekly administration of Cetuximab with a first 
loading dose as per the technical sheet [7]. In the comparison scenario the base case 
administration was replaced with every-other-week (EOW) administration at 50% or 100% 
of the eligible population for the maintenance therapy only. In the base case scenario the 
schedule included a dose of 250 mg per BSA [7] compared to one dose of 500 mg per BSA 
every two weeks (alternative scenario). Moreover, the expense simulations have been 
broken down in cost analyses per mg of drug used (base case) and per required ampoule 
(included in sensitivity analysis). The model assumed an average BSA of 1.8 m2 [21], details 
on the treatment schedules are reported in Table 2. 
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Cost Parameters 
According to the dosing schedules (Table 2), the price of Cetuximab was used net of 
discounts by law. Furthermore, the costs associated with patients’ management have been 
included. Precisely, we estimated the cost of medical examinations required for drug 
administration and patient management. We considered a cost of €85 per medical 
examination for each administration. This includes the cost of the physician, nurse, 
consumption material, for the drug administration and distribution by the hospital pharmacy 
[22]. Moreover, indirect costs associated with the loss of productivity (absence from work) 
of the patient or caregivers were estimated. The model assumed the loss of one working day 
every time the drug was administered to the patient in the hospital setting. We calculate 
these by considering an average salary per hour of €27.8 [23, 24], which corresponds to a 
daily salary of €200.2 [23, 24] before tax, (Table 2). 
Finally, the model did not consider efficacy and safety differences between the two 
schedules and chemotherapy costs were not included as they were the same for the two 
strategies.  
Table 2 – Parameters of patient definition and therapy cost 
Parameters of patient definition mCRC RAwt Parameter Ref 
BSA patient, m2 1.8 [21] 
Weekly ampoule weekly I CET / 400mg per BSA 8.0 / 720mg [7] 
Weekly ampoule II CET_Weekly/ 250mg per BSA 5.0 / 450mg [7] 
Weekly ampoule CET_EOW/500 mg per BSA 9.0 / 900mg Assumption 
Number of lost working days per medical examination 1.0 Assumption 
Cost parameters Cost Ref 
Ampoule price 100 mg € 153.6 AIFA 
Cost of medical examination per administration € 85.0 [22] 
Cost of working day Italy € 200.2 [23, 24] 
 
Sensitivity Analysis 
In order to account for the model uncertainty due to parameters and the consequent 
variability on results, a deterministic one-way sensitivity analysis was performed. This was 
performed by varying one parameter of the model at once, depending on the variability 
observed in the literature or assumed by the authors as advised by clinical experts. The 
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consequence of such variations were observed on BI results.  Specifically, the following 
scenarios have been considered and applied on the 100% EOW scenario compared to base 
case: 
 
 mCRC RAS wt patients treated with Cetuximab (base-case=55.0%): Min=45% 
- Max 65% 
 Cost of drug by number of ampoules required for the administration (base 
case=cost per mg) 
 Working days lost per visit (base case=1 day lost): Min = 0 – Max = 2 
 Incidence of CRC (base case=0.087): Min=0.078% - Max: 0.096%,  
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Results 
We estimated a total of 2,549 patients diagnosed with mCRC RAS wt. In the base 
case scenario these were subjected to first-line treatment with Cetuximab once a week and 
compared with an EOW administration schedule applied to 50% and 100% of patients. In 
the next sections the results of these comparisons are illustrated. 
 
Base case vs EOW 50% Scenario 
When 50% of patients were subjected to bi-monthly administration with Cetuximab, the 
budget was expected to decrease from €100.6 million in the base case to €92.8 million in 
the scenario, resulting in an overall net savings of 8% or €7.8 million. The greatest savings 
came from indirect costs that were reduced by €5.1 million corresponding to 25% followed 
by those related to the management of patients and drug administration (-24% with respect 
to base case). Drug costs showed a smaller saving of approximately €528.4 thousand (-
0.7%). 
Table 3 – Budget Impact results base case vs EOW 50% Scenario  
ITALY Expense 
10-month results Base case EOW 50% Scenario BUDGET IMPACT 
Drug cost (calculation per mg) € 43.328.094 € 42.799.703 -€ 528.391 
Management cost/ drug administration € 5.199.649 € 3.899.737 -€ 1.299.912 
Indirect costs € 12.246.703 € 9.185.027 -€ 3.061.676 
TOTAL EXPENSE € 60.774.446 € 55.884.467 -€ 4.889.979 
     1 Week EOW 50% Scenario Tot treated patients 
Treated patients base case 2,549 0 2,549 
Treated patients 50% Scenario 1,274 1,274 2,549 
 
 
Base case vs EOW 100% Scenario 
An EOW administration of Cetuximab on 100% of the eligible population resulted in 
a greater reduction on the 10-months budget. Precisely, the budget was reduced to €84.9 
million compared to the base case scenario (€100.6 million), resulting in an overall cost 
savings of 16% or €15.6 million. As reported in Table 4, the greatest savings were due to 
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indirect costs (over 50% reduction), from €20.4 million in the base case to €10.2 in the 
scenario. Management costs, including cost of medical examinations and drug 
administration, decreased by €4.3 million, resulting in a reduction by roughly 50% 
compared to the base case (€8.6 million). Drug costs were the smallest category driver of 
cost reduction with a savings of €1.05 million.  
Table 4 – Budget Impact results base case vs EOW 100% Scenario  
ITALY Expense 
10-month results Base case EOW 100% Scenario BUDGET IMPACT 
Drug cost (calculation per mg) € 71,508,968 € 70,452,186 -€ 1,056,783 
Management cost/drug administration € 8,666,082 € 4,333,041 -€ 4,333,041 
Indirect costs € 20,411,171 € 10,205,586 -€ 10,205,586 
TOTAL EXPENSE € 100,586,221 € 84,990,812 -€ 15,595,409 
    1 Week EOW 100% Scenario Tot treated patients 
Treated patients base case 2,549 0 2,549 
100% treated patients Scenario 0 2,549 2,549 
 
Sensitivity Analysis  
Figure 1 shows the variables with the highest impact on the model results. The model 
was most sensitive to the number of working days lost by patient or caregivers that 
accounted for approximately 41% of variation in model outputs, with budget impact results 
ranging from -€5.4 million to -€25.8 million in the 100% EOW scenario compared to base 
case. The adoption of cost per ampoule would cause incremental savings of €4.8 million 
compared to the base case, resulting as the second most influential category over model 
variability. The variation of +/-10% hypothesized over the incidence of mCRC RAS wt 
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patients and the number of those treated with Cetuximab resulted in a relative small impact 
on the model results accounting for 11% and 9% on the overall variability respectively. 
Figure 1 – One-way sensitivity analysis - Case base Budget Impact vs EOW 100% scenario
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Discussion 
This budget impact analysis was developed to estimate the economic consequences 
of the adoption of an EOW administration schedule among patients diagnosed with mCRC 
in Italy. Two different scenarios, when 50% and 100% of patients were treated with the bi-
monthly schedule, have been analysed compared to a base case in which the standard of care 
of a weekly administration was included. The model results showed a net savings ranging 
from €7.8 million to €15.6 million when adopting the 50% or 100% scenario compared to 
base case respectively. In both cases, indirect costs were the main driver of cost savings, 
accounting approximately for the 65% of the overall reduction. 
Several factors should be considered when interpreting the results of this analysis. As such, 
a number of simplifying assumptions were made to develop the model that may impact the 
study findings. First, the epidemiological parameters, based on published national and 
international reports may result in an overestimation as well as underestimation of the real 
number of patients treated with Cetuximab in the Italian context. This aspect was taken into 
account in the sensitivity analysis where a variation of +/- 10% has been considered 
accordingly to expert opinions to enable a better estimation of a plausible range. Secondly, 
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the model may have resulted in an underestimation of direct costs due to the limited number 
of cost items included in the analysis. In particular, the model considered only the costs of 
Cetuximab as a drug therapy while the costs of chemotherapy, adverse events and/or disease 
progression, were not included. This was due to the assumption, validated by clinical 
experts, that such items would remain unchanged when switching from a weekly to an EOW 
schedule, thus their inclusion would not affect the study results. a third limitation was 
represented by the lack of information on the number of working days lost by patients or 
caregivers that may influence the estimation of indirect costs. Also, presenteeism or 
absenteeism due to adverse events, the reduced productivity and the risk of dismissal were 
not taken into account resulting in a further potential underestimation of the budget impact 
related to indirect costs.  
 
Conclusions 
This budget impact analysis demonstrated that the adoption of an EOW administration 
schedule of Cetuximab among patients diagnosed with mCRC in Italy is expected to reduce 
direct and indirect costs substantially. Therefore, in addition to the therapeutic equivalence 
of the two indications of Cetuximab as already demonstrated in previous published articles, 
the present study provided a measure of the cost savings that would therefore allow a more 
efficient use of resources at hospital base. 
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